Primary immune thrombocytopenia is a chronic autoimmune disorder characterized by immune-mediated platelet destruction and impaired platelet production. Patients with anti-GPIb/IX autoantibodies often experience particularly severe disease and respond poorly to corticosteroids, IVIG, rituximab, and thrombopoietin receptor agonists.

This Phase I study evaluated BCMA-directed CAR-T therapy in patients with refractory primary ITP who remained autoantibody-positive despite multiple prior treatment failures.

Safety Outcomes-

• Cytokine Release Syndrome (CRS): Grade 1–2 CRS only; No Grade ≥3 CRS reported.

• Neurotoxicity: No ICANS observed.

• Hematologic Toxicity: No Grade ≥3 ICAHT reported.

• Infections: No Grade ≥3 infections observed.

• Overall Safety: Favorable tolerability across all doses; No unexpected safety signals identified.

KOL Insights-

“The durable disappearance of anti-platelet antibodies together with reconstitution of a less inflammatory immune repertoire suggests BCMA CAR-T may be achieving true immune resetting rather than transient immunosuppression.”– Expert Opinion

“These findings add to the growing evidence that cellular therapies may eventually move beyond cancer and become transformative treatments for severe autoimmune diseases.”– Expert Opinion

Conclusion-

Primary immune thrombocytopenia (ITP) is a rare autoimmune disorder with an estimated prevalence of approximately 10–20 cases per 100,000 individuals worldwide. While many patients respond to corticosteroids, IVIG, rituximab, or thrombopoietin receptor agonists, a subset develops chronic refractory disease associated with persistent autoantibody production, recurrent bleeding risk, and substantial treatment burden.

This first-in-human study provides compelling evidence that BCMA CAR-T therapy may fundamentally alter the disease course of refractory primary ITP. All evaluable patients achieved complete responses, most experienced durable drug-free remissions, and extensive translational analyses demonstrated profound immune reprogramming characterized by elimination of pathogenic plasma cells, suppression of autoantibodies, and restoration of a healthier immune landscape. Although limited by small patient numbers and short follow-up, the trial represents a major milestone for cellular therapy in autoimmune disease and supports further investigation of BCMA CAR-T as a potentially curative strategy for refractory ITP and related antibody-mediated disorders.